Skip to main content

Advertisement

SpringerLink
Log in

Surrogate biomarkers for anti-angiogenic therapy for advanced colorectal cancer

  • Published:
Current Colorectal Cancer Reports

Abstract

Vascular endothelial growth factor (VEGF)—over-expressed in colorectal cancer—is associated with disease progression and inferior survival. Based on successful, randomized, phase III trials, anti-VEGF therapeutics have entered clinical practice. Bevacizumab, a VEGF-specific antibody, was the first anti-angiogenic agent to be approved by the Food and Drug Administration to be used in combination with standard chemotherapy in the first and second line of treatment in metastatic colorectal cancer. VEGF-targeted therapy may lead to indirect killing of cancer cells by damaging tumor blood vessels and may increase the radiosensitivity of tumor-associated endothelial cells. VEGF blockade can also normalize tumor vasculature thereby leading to greater tumor oxygenation (a known radiosensitizer) and drug penetration. A dose-escalation phase I trial has demonstrated that the combination of bevacizumab at the 5-mg/kg dose with radiochemotherapy was well tolerated by patients with rectal cancers. In addition, results from an array of correlative studies have demonstrated that bevacizumab has antivascular effects and supported the normalization hypothesis. The ongoing phase II study will further elucidate the mechanisms of action and efficacy of bevacizumab in locally advanced rectal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Chin KF, Greenman J, Gardiner E, et al.: Preoperative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 2000, 83:1425–1431.

    Article  PubMed  CAS  Google Scholar 

  2. Hyodo I, Doi T, Endo H, et al.: Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998, 34:2041–2045.

    Article  PubMed  CAS  Google Scholar 

  3. Nanashima A, Ito M, Sekine I, et al.: Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers. Dig Dis Sci 1998, 43:2634–2640.

    Article  PubMed  CAS  Google Scholar 

  4. Cascinus S, Graziano F, Catalano V, et al.: Vascular endothelial growth factor (VEGF), p53, and BAX expression in node positive rectal cancer. Pro Am Soc Clin Oncol 2001, 20:595.

    Google Scholar 

  5. Kabbinavar F, Hurwitz H, Fehrenbacher L, et al.: Phase II trial comparing rhuMAB VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus 5-fluoroouracil/leucovorin (FU/LV) to FU/LV) alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60–65.

    Article  PubMed  CAS  Google Scholar 

  6. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 2004, 350:2335–2342.

    Article  PubMed  CAS  Google Scholar 

  7. Giantonio BJ, Levy DE, O’Dwyer PJ, et al.: A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 2006, 17:1399–1403.

    Article  PubMed  CAS  Google Scholar 

  8. National Cancer Institute: Bevacizumab (Avastin ™) for Metastatic Colorectal Cancer. http://www.cancer.gov/newscenter/pressreleases/bevacizumab. Accessed February 2, 2007.

  9. Lee CG, Heijn M, di Tomaso E, et al.: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000, 60:5565–5570.

    PubMed  CAS  Google Scholar 

  10. Kozin SV, Boucher Y, Hicklin DJ, et al.: Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenograts. Cancer Res 2001, 61:39–44.

    PubMed  CAS  Google Scholar 

  11. Winkler F, Kozin S, Tong R, et al.: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metallproteinases. Cancer Cell 2004, 6:553–562.

    PubMed  CAS  Google Scholar 

  12. Tong RT, Boucher Y, Kozin SV, et al.: Vascular normalization by VEGFR2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64:3731–3736.

    Article  PubMed  CAS  Google Scholar 

  13. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Med 2001, 7:987–989.

    Article  PubMed  CAS  Google Scholar 

  14. Jain RK: Normalization of tumor vasculature: an emerging concept in anti-angiogenic therapy. Science 2005, 307:58–62.

    Article  PubMed  CAS  Google Scholar 

  15. Willett CG, Boucher Y, di Tomaso E, et al.: Direct evidence that the VEGF-specific antibody bevacizumab has anti-vascular effects in human rectal cancer. Nature Med 2004, 10:145–147.

    Article  PubMed  CAS  Google Scholar 

  16. Willett CG, Boucher Y, Duda DG, et al.: Surrogate markers for antiangiogenic therapy and dose limiting toxicities for Bevacizumab with radio-chemotherapy: continued experience of a Phase I trial in rectal cancer patients. J Clin Oncol 2005, 23:8136–8139.

    Article  PubMed  Google Scholar 

  17. Duda, DG, Cohen KS, di Tomaso E, et al.: Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for anti-angiogenic therapy. J Clin Oncol 2006, 24:1449–1453.

    Article  PubMed  CAS  Google Scholar 

  18. Drevs J, Medinger M, Mross K, et al.: Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors [abstract]. J Clin Oncol 2005, 23(Suppl):3002.

    Google Scholar 

  19. Willett CG, Duda DG, di Tomaso E, et al.: Complete pathological response in T4 locally advanced rectal cancer after treatment with bevacizumab and standard radiochemotherapy. Nat Clin Pract Oncol 2007, In press.

  20. Motzer RJ, Michaelson MD, Redman BG, et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16–24.

    Article  PubMed  CAS  Google Scholar 

  21. Dowlati A, Gray R, Johnson DH, et al.: Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2006, 24(Suppl):7027.

    Google Scholar 

  22. Batchelor TT, Sorensen AG, di Tomaso E, et al.: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83–95.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Duke University Medical Center, Box 3085, Durham, NC, 27710, USA

    Christopher G. Willett MD

Authors
  1. Christopher G. Willett MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel G. Duda DMD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rakesh K. Jain PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher G. Willett MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Willett, C.G., Duda, D.G. & Jain, R.K. Surrogate biomarkers for anti-angiogenic therapy for advanced colorectal cancer. Curr colorectal cancer rep 3, 94–98 (2007). https://doi.org/10.1007/s11888-007-0007-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-007-0007-5

Keywords

Search

Navigation